Copyright (c) 2023 Maykel González Torres, Gerardo Leyva Gómez, María Luisa Del Prado-Audelo, Hernán Cortés, Jonathan J. Magaña
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
Recombinant Antibodies to Face SARS-CoV-2 Syndemic
Corresponding Author(s) : Maykel González Torres
Cellular and Molecular Biology,
Vol. 69 No. 7: Issue 7
In recent years, increasing interest has been paid to using antibody-based therapies for clinical applications. However, it is unclear whether recombinant antibodies can be combined with other scientific approaches to generate innovative solutions for mitigating severe acute respiratory syndrome coronavirus 2. In this context, the increase in this virus transmission, the number of infected people, and the interaction between social and biological processes have led to a syndemic, exacerbating the public health problem. Here, we argue about recent advances in recombinant antibody strategies and the perspective of using them to face this syndemic. Thus, the most promising methods in sample readiness, potency, and reduction of manufacturing time frame have been highlighted.
Download CitationEndnote/Zotero/Mendeley (RIS)